Land: Bretland
Tungumál: enska
Heimild: MHRA (Medicines & Healthcare Products Regulatory Agency)
Methotrexate
Advanz Pharma
L04AX03
Methotrexate
2.5mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 10010300; GTIN: 5021691107828
Package leaflet: Information for the patient Methotrexate 2.5 mg Tablets methotrexate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. -Keep this leaflet. You may need to read it again. -If you have any further questions, ask your doctor, pharmacist or nurse. -This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. -If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Methotrexate 2.5 mg Tablets are and what they are used for 2. What you need to know before you take Methotrexate 2.5 mg Tablets 3. How to take Methotrexate 2.5 mg Tablets 4. Possible side effects 5. How to store Methotrexate 2.5 mg Tablets 6. Contents of the pack and other information 1. What Methotrexate 2.5 mg Tablets are and what they are used for Methotrexate 2.5 mg Tablets are one of a group of medicines called antimetabolites which affect cell growth, including the growth of cancer cells. Methotrexate can be used to treat severe cases of psoriasis (a skin disease) and rheumatoid arthritis (a disease of the joints). It is usually used for patients who have tried other treatments but their illness has not improved. It helps patients with psoriasis by killing the cells in the skin which are growing too quickly. It is these fast growing cells which cause the raised patches of skin in psoriasis. In the treatment of rheumatoid arthritis, methotrexate is thought to stop or reduce inflammation in the joints by altering the body's defence mechanism in the immune system. Methotrexate can also be used to treat several kinds of cancer, in particular: acute leukaemias Non-Hodgkin’s lymphoma soft tissue and bone sarcomas solid tumours like breast, lung, head and neck, bladder, cervical, ovarian and testicular cancer. Methotrexate can be given al Lestu allt skjalið
OBJECT 1 METHOTREXATE 2.5 MG TABLETS Summary of Product Characteristics Updated 23-Jan-2020 | ADVANZ Pharma • 1. Name of the medicinal product • 2. Qualitative and quantitative composition • 3. Pharmaceutical form • 4. Clinical particulars • 4.1 Therapeutic indications • 4.2 Posology and method of administration • 4.3 Contraindications • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation • 4.7 Effects on ability to drive and use machines • 4.8 Undesirable effects • 4.9 Overdose • 5. Pharmacological properties • 5.1 Pharmacodynamic properties • 5.2 Pharmacokinetic properties • 5.3 Preclinical safety data • 6. Pharmaceutical particulars • 6.1 List of excipients • 6.2 Incompatibilities • 6.3 Shelf life • 6.4 Special precautions for storage • 6.5 Nature and contents of container • 6.6 Special precautions for disposal and other handling • 7. Marketing authorisation holder • 8. Marketing authorisation number(s) • 9. Date of first authorisation/renewal of the authorisation • 10. Date of revision of the text 1. Name of the medicinal product Methotrexate 2.5 mg Tablets 2. Qualitative and quantitative composition Each tablet contains methotrexate sodium equivalent to 2.5 mg of methotrexate. Excipient(s) with known effect Lactose monohydrate- 66.166 mg per tablet For the full list of excipients, see section 6.1. 3. Pharmaceutical form Tablet Round, biconvex, yellow tablets, engraved with “2.5” on one side. Scored in half on the other side and engraved with 'M' above the score line and '1' below it. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. Clinical particulars 4.1 Therapeutic indications Methotrexate is a folic acid antagonist and is classified as an antimetabolite cytotoxic agent. Methotrexate has been used to produce regression in a wide range of neoplastic conditions including acute le Lestu allt skjalið